抗黑色素瘤分化相关基因5抗体阳性皮肌炎相关间质性肺病患者的纵向研究
该研究纳入216例抗MDA5抗体阳性皮肌炎相关间质性肺病患者并随访至96个月,85例(39.3%)死亡,其中89%的死亡发生在诊断后第一年;存活第一年的70例患者长期随访中血清学标志物和肺功能显著改善,早期应用抗纤维化治疗有助于改善长期肺功能。
要点
- 216例抗MDA5抗体阳性皮肌炎相关间质性肺病患者中85例(39.3%)死亡,89%的死亡发生在诊断后第一年。
- 存活第一年的70例患者长期随访中抗MDA5抗体等血清学标志物随时间显著改善。
- 早期应用抗纤维化治疗有助于改善长期肺功能。
核心结论
- 抗MDA5抗体阳性皮肌炎相关间质性肺病患者尽管接受积极治疗,死亡率仍高。
- 存活第一年的患者在长期随访中血清学标志物和肺功能显著改善。
研究设计与样本
- 纳入216例确诊为抗MDA5抗体阳性皮肌炎相关间质性肺病的患者,进行长达8年的纵向随访以分析长期生存率。
- 在基线和每个时间终点收集人口学和临床变量;对存活第一年的70例患者分析长期血清学和呼吸结局。
主要发现
- 随访至96个月期间共85例(39.3%)死亡,其中89%的死亡发生在诊断后第一年。
- 70例患者的长期结局显示,包括抗MDA5抗体在内的血清学标志物随时间显著改善。
- 影像学表现和肺功能在随访期间也显著改善,尤其在快速进展型间质性肺病组,通过高分辨率CT评分、估计用力肺活量、估计肺一氧化碳弥散量和呼吸困难评分评估。
- 早期应用抗纤维化治疗有助于改善长期肺功能。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: To describe the 8-year longitudinal study and long-term prognosis of a large inception cohort of anti-melanoma differentiation-associated gene 5 (MDA5) antibody-positive (MDA5+) DM-interstitial lung disease (ILD) patients. METHODS: In total, 216 patients diagnosed with MDA5+ DM-ILD were enrolled and followed up to analyse long-term survival rate. Demographic and clinical variables were collected at baseline and each temporal end point. Seventy patients who survived the first year were analysed for the long-term serological and respiratory outcomes. RESULTS: A total of 85 patients (39.3%) died during the follow-up period up to 96 months, with 89% of the deaths occurring in the first year after diagnosis. Long-term outcome was reported in 70 patients. Serological markers including anti-MDA5 antibody showed significant improvement with time. Radiographic findings and pulmonary function also improved notably in the follow-up period, especially in rapidly progressive ILD group, as measured by high-resolution computed tomography imaging scores, the estimated forced vital capacity, estimated diffusing capacity of lung carbon monoxide and dyspnoea scores. Early application of anti-fibrosis therapy helped to improve long-term pulmonary function. CONCLUSIONS: MDA5+ DM-ILD patients had a high mortality rate despite aggressive treatment. Patients who survived the first year usually showed a significant improvement in serological markers and pulmonary function during the long-term follow-up.
引用
- Lian X, Ye Y, Zou J, et al. Longitudinal study of patients with antimelanoma differentiation-associated gene 5 antibody-positive dermatomyositis-associated interstitial lung disease. Rheumatology (Oxford). 2023. PMID: 36130290. doi:10.1093/rheumatology/keac525
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。